Company / Interest Expense
Charles River Laboratories Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$73.9M
FY2023
5-year range
$60.9M / $86.4M
FY2019-FY2023
Trend
-14.5%
vs FY2022
Sector context
#22 of 46
Health Care
What the data says
At $74M, Charles River Laboratories's interest expense ranks #25 of 46 in the Health Care sector. Interest Expense has fluctuated over the past 8 years, ranging from $28M in FY2016 to $86M in FY2022.
Based on SEC 10-K filings.
$74M in FY2023 with a 5-year CAGR of +3.0%.
Increased from $61M to $74M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +5.0%
- 5-Year CAGR
- +3.0%
- 10-Year CAGR
- -
Sector benchmark
#25 of 46 in Health CareTop 52% of 46This company $73.9M Sector average $293.8M
▼
-74.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.0%, indicating consistent growth.
- In FY2023, interest expense decreased 14.5% year-over-year.
- Ranks #22 out of 46 companies in the Health Care sector.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $73.9M | -14.5% |
| FY2022 | $86.4M | +42.0% |
| FY2021 | $60.9M | -4.5% |
| FY2020 | $63.8M | +114.2% |
| FY2019 | $29.8M | -53.3% |
| FY2018 | $63.8M | +114.2% |
| FY2017 | $29.8M | +7.5% |
| FY2016 | $27.7M | +32.1% |
As of FY2023 · SEC 10-K · Updated Jul 4, 2026